Prostate Cancer

Evan Y. Yu, MD, professor, Department of Medicine, Division of Oncology, University of Washington, Seattle Cancer Care Alliance, discusses how comorbidities factor into treatment choice for patients with castration-sensitive prostate cancer.

Combining olaparib (Lynparza) with abiraterone acetate (Zytiga) reduced the risk of disease progression or death by 35% compared with abiraterone alone in pretreated patients with metastatic castration-resistant prostate cancer.

Maha Hussain, MD, FACP, FASCO, Genevieve Teuton Professor of Medicine, Deputy Director, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, discusses findings with PARP inhibitors in prostate cancer.

Daniel J. George, MD, professor of medicine, surgery, member, Duke Cancer Institute, discusses the results of the prospective multicenter Abi Race trial, which compared outcomes of African-American and Caucasian patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (Zytiga) and prednisone.

Black men with metastatic castration-resistant prostate cancer may experience greater benefits from chemotherapy and hormone-targeting treatment than their white counterparts.

Andy Hahn, MD, resident, University of Utah School of Medicine, discusses patient selection for abiraterone acetate (Zytiga) versus docetaxel in metastatic hormone-sensitive prostate cancer (mHSPC).

Peter L. Choyke, MD, FACP, director, Molecular Imaging Program, head, Imaging Section, Center for Cancer Research, National Cancer Institute (NCI), discusses the importance of multidisciplinary care in prostate cancer.

Key opinion leaders spoke with OncLive ahead of the 2018 ASCO Annual Meeting to share the top abstracts they believe could have the greatest impact on clinical practice and patient outcomes across lymphomas, gastrointestinal cancers, genitourinary cancers, and lung cancer.

James L. Godwin, MD, physician, Sidney Kimmel Cancer Center, Thomas Jefferson Hospital, discusses immunotherapy efforts in prostate cancer.

The FDA has approved a new formulation of abiraterone acetate in combination with methylprednisolone as a treatment for men with metastatic castration-resistant prostate cancer.

Edouard J. Trabulsi, MD, FACS, professor, co-director, Multidisciplinary Genitourinary Oncology Center, Prostate Diagnostic Center, vice chair of research, director, Division of Urologic Oncology, Department of Urology, Sidney Kimmel Cancer Center, discusses postoperative radiation in patients with prostate cancer.

Apalutamide (Erleada) lowered the risk of PSA progression by 94% in patients with nonmetastatic castration-resistant prostate cancer, according to a posthoc analysis from the phase III SPARTAN trial.

The US Preventive Services Task Force has concluded that there is a small mortality benefit associated with prostate-specific antigen-based prostate cancer screening for men aged 55 to 69 years, a departure from earlier guidance.

Data from recent trials in metastatic hormone-sensitive prostate cancer have demonstrated the heterogeneous nature of prostate cancer and its subtypes, highlighting the importance of a more cautious approach in choosing therapies for patients.

Peter L. Choyke, MD, FACP, director, Molecular Imaging Program, head, Imaging Section, Center for Cancer Research, National Cancer Institute, discusses the combination of imaging techniques in prostate cancer.

The National Comprehensive Cancer Network has overhauled its guidelines for managing prostate cancer with a greater emphasis on risk stratification for molecular testing and therapy choices.

James B. Yu, MD, discusses techniques with radiation therapy, potential roadblocks, and the importance of genomic testing in treating patients with prostate cancer.